We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,909

China-Australia FTA: implications on the Chinese health industry
  • King & Wood Mallesons
  • Australia, China
  • June 18 2015

On June 17, 2015, the China-Australia Free Trade Agreement (“ChAFTA”) was officially signed by Australia’s Trade Minister Andrew Robb and China’s


US investors set to establish wholly foreignowned hospitals in China
  • Winston & Strawn LLP
  • China
  • February 5 2015

Following up our previous Special Alert on the opening up of China's healthcare sector to foreign investors, two major US groups appear to have taken


China: multinationals continue to adapt to active enforcement environment
  • Skadden Arps Slate Meagher & Flom LLP
  • China, USA
  • January 27 2015

Over the past few years, the U.S. authorities have continued their aggressive stance toward corrupt activity in China; 2014 saw significantly


A year of global change 2015: what multinational life sciences companies should expect in China
  • Sidley Austin LLP
  • China
  • March 4 2015

With China marching into the Year of the Ram, multinational life sciences companies should anticipate and be prepared for regulatory changes and


Biosimilars are regulated differently in China
  • Ropes & Gray LLP
  • China, European Union, USA
  • July 22 2015

The Centre for Drug Evaluation (CDE) the technical review body under the China Food and Drug Administration (CFDA) released the Technical


China encourages foreign investment in senior care services
  • McDermott Will & Emery
  • China
  • January 7 2015

In late 2014, the Ministry of Commerce and the Ministry of Civil Affairs of China jointly issued the Announcement Encouraging Foreign Investors to


U.S.-China Commission study provides policy recommendations to help U.S. exporters compete in China’s growing medical device and pharmaceutical market
  • Kelley Drye & Warren LLP
  • China, USA
  • January 28 2015

A recent report issued by the U.S.-China Economic and Security Review Commission (USCC) highlights why the Chinese market is central to the business


China liberalizes drug pricing control
  • Ropes & Gray LLP
  • China
  • May 12 2015

Beginning June 1, 2015, the vast majority drugs in China, except for narcotic and Type 1 psychotropic drugs, will be free from government-set pricing


依赖遗传资源申请的 PCT 现状及中国专利法的相关规定
  • Kangxin Partners PC
  • China, Global
  • October 24 2014

作为生物多样性最丰富的国家之一我国于 1992 年 6 月 11 日签署了生物多样性公约随后我国人大常委会于 1992 年 11 月 7 日批准加入该公约1993 年 1 月 5 日正式缴存加入书是最早正式加入该公约的国家之一生物多样性公约于 1993 年 12 月 20 日生效


International news: focus on compliance - winter 2014
  • McDermott Will & Emery
  • China, European Union, Germany, Global, USA
  • December 2 2014

As regulatory oversight of companiesfrom Sarbanes Oxley and the Dodd-Frank Act to the Foreign Corrupt Practices Act (FCPA) and the UK Bribery